Jay Feingold - 07 Oct 2021 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Medical Officer
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold
Issuer symbol
PYXS
Transactions as of
07 Oct 2021
Net transactions value
$0
Form type
3
Filing time
07 Oct 2021, 21:15:22 UTC
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PYXS Stock Option (Right to buy) 07 Oct 2021 Common Stock 157,257 $8.71 Direct F1
holding PYXS Stock Option (Right to buy) 07 Oct 2021 Common Stock 17,517 $8.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options vest 25% on the first anniversary of the September 13, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2 These stock options vest 25% on the first anniversary of the closing of the Issuer's initial public offering, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney